Psoriasis is often accompanied by itch, but the mechanisms behind this symptom remain elusive. Dynamic changes in epidermal innervation have been observed under chronic itch conditions. Therefore, we investigated whether epidermal innervation is altered in the imiquimod-induced psoriasis mouse model, whether blockade of neurotrophic growth factor signaling can reduce these changes, and whether this system can impact psoriatic itch. Over the 7-day time course of imiquimod treatment, the density of epidermal nonpeptidergic nerves significantly increased, whereas the density of peptidergic nerves significantly decreased. The nonpeptidergic epidermal nerves expressed glial cell line-derived neurotrophic factor (GDNF) family receptor GFRa-1 and GFRa-2, the ligand-binding domains for GDNF and neurturin (NRTN). The NRTN mRNA expression was elevated in the skin of imiquimodtreated mice, whereas the GDNF mRNA expression was decreased. Treatment of imiquimod-challenged mice with an NRTNneutralizing antibody significantly reduced nonpeptidergic nerve density as well as spontaneous scratching. These results indicate that NRTN contributes to an increase in the epidermal density of nonpeptidergic nerves in the imiquimod-induced psoriasis model, and this increase may be a factor in chronic itch for these mice. Therefore, inhibition of NRTN could be a potential treatment for chronic itch in psoriasis.
Introduction
Chronic itch is the most troublesome symptom of psoriasis, a chronic autoimmune skin disease of scaling and inflammation. Epidermal hyperinnervation by itch-signaling fibers is considered to be one cause of chronic itch, 32 and increased epidermal nerve density has been frequently reported in humans with chronic itch conditions, including psoriasis, 12, 18, [29] [30] [31] [32] with some exceptions. 19, 24 Nociceptive fibers are expressed throughout the epidermis and often categorized as peptidergic or nonpeptidergic fibers. 7 The former contain the neuropeptides calcitonin generelated peptide (CGRP) and/or substance P, whereas the latter express the purinergic receptor P2X3 and isolectin B4. Ablation of the peptidergic or nonpeptidergic subset of fibers produces modality-specific deficits in response to heat and mechanical stimuli, respectively. 8, 40 Enhanced intraepidermal nonpeptidergic nerve density has been reported previously in animal models of dry skin itch. 25, 34 Most nonpeptidergic sensory neurons express glial cell linederived neurotrophic factor (GDNF) family receptor GFRa-1 and/or GFRa-2, which show preferential binding for GDNF and neurturin (NRTN), respectively. 36 These neurotrophic growth factors are important for the development and maintenance of nonpeptidergic sensory neurons. 5, 9, 13, 15, 35, 41 As such, overexpression of these growth factors could lead to increased nonpeptidergic nerve density, possibly leading to increased itch.
We have reported that the imiquimod-induced psoriasis mouse model is useful for the investigation of chronic itch in psoriasis. 23 Using this model, we presently investigated whether the epidermal density of nonpeptidergic nerves and the expression of their neurotrophic growth factors (GDNF and NRTN) are increased in psoriasis-like skin. Because this model exhibits spontaneous scratching that is histamine-dependent in the early phase (day 2) and histamine-independent in the late phase (day 7), we measured nerve fiber density at these time points. In addition, we tested whether inhibition of NRTN could affect the density of intraepidermal fibers and spontaneous scratching behavior.
Materials and methods

Imiquimod application and drug treatment
Experiments were performed using adult male C57BL/6J mice (19-29 g ) under a protocol approved by the Temple University Animal Care and Use Committee. Fur on the rostral back was trimmed with electric clippers and then removed with an electric shaver. Each mouse received a daily topical application of 62.5 mg Aldara cream (5% imiquimod, Meda Pharmaceuticals) on the shaved back skin (2.5 3 2 cm) for 7 consecutive days.
In NRTN-neutralizing antibody experiments, each animal received an intradermal injection of either goat IgG control antibody (0.4 mg/50 mL; R&D Systems, Minneapolis, MN) or a neutralizing antibody to mouse NRTN (low dose: 0.04; high dose: 0.4 mg/50 mL; AF477; R&D Systems) 11 into the imiquimod treatment area after behavior recording and before each topical application of Aldara cream for days 1 to 7.
Behavioral tests
Mice were habituated twice to a Plexiglas recording arena for 60 minutes before testing. At baseline (day 0) and 20 to 22 hours after each topical application, mice were videotaped from above for 60 minutes. The number of videotaped scratch bouts was counted by a trained observer blinded to the treatment condition. A scratch bout was defined as one or more rapid back-and-forth hind paw motions directed toward and contacting the treated area and ending with licking or biting of the toes or placement of the hind paw on the floor. Hind paw movements directed away from the treated area (eg, ear scratching) and grooming movements were not counted.
2-4 Scratch bouts were counted for mice treated with imiquimod alone, imiquimod plus goat IgG control, imiquimod plus low-dose NRTN-neutralizing antibody, and imiquimod plus high-dose NRTN-neutralizing antibody at days 0, 2, and 7.
Quantitative real-time polymerase chain reaction
On days 0, 1, and 6 of imiquimod treatment, animals were euthanized under sodium pentobarbital anesthesia, and skin samples were immediately collected, submerged in RNA later (Qiagen, Valencia, CA), and stored at 280˚C. Total RNA was extracted using Direct-zol RNA Mini Prep (Zymo Research, Irvine, CA). Reverse transcription of 0.5 mg total RNA was performed using ProtoScript II First Strand cDNA Synthesis Kit (New England Biolabs, Ipswich, MA). Amplification of GAPDH cDNA was used for normalization. Real-time polymerase chain reaction was performed using Fast Plus EvaGreen qPCR Master Mix (Biotium, Hayward, CA) on a 7500 Real-Time PCR System (Applied Biosystems, Grand Island, NY). Forty cycles of amplification were performed involving sequential denaturation at 95˚C for 5 seconds, annealing at 55 to 60˚C for 5 seconds, and extension at 72˚C for 33 seconds. Assays were validated using serial dilutions and confirmation of equal amplification efficiencies of the cDNA of interest and the GAPDH cDNA. Fold differences in expression were calculated using the comparative DC t method by standardizing against GAPDH expression. The following primers were used for analyses of gene expression: mGDNF-F, 59CCAGTGACTCCAATATGCCTG39; mGDNF-R, 59CTCTGCGACCTTTCCCTCTG39; mNRTN-F, 59GGGCTA-CACGTCGGATGAG39; mNRTN-R, 59CTTCTCCTCCGAGG-CATAGC39; mGAPDH-F, 59TCCACTGGCGTCTTCAC39; mGAPDH-R, 59GGCAGAGATGATGACCCTTTT39.
Immunohistochemistry
On days 0, 2, and 7 of imiquimod treatment (with or without drug treatment), animals were euthanized under sodium pentobarbital anesthesia, and the skin was immediately dissected. The skin was fixed in Zamboni Fixative solution (Newcomer Supply, Middleton, WI) followed by 30% sucrose, frozen in optimal cutting temperature compound (Tissue-Tek, Sakura Finetek, Torrance, CA), and cut in 16-and 40-mm sections on a cryostat. The 16-mm sections were incubated with 5% donkey serum and 0.2% Triton X-100 in phosphatebuffered saline (PBS), then immunostained with a goat NRTN antibody (10 mg/mL; R&D Systems Inc) at 4˚C overnight, followed by incubation with the corresponding secondary antibody conjugated with Alexa Fluor 488 (1:300; Life Technologies Inc, Grand Island, NY) for 2 hours.
The 40-mm sections were incubated with 5% donkey serum and 0.2% Triton X-100 in PBS and then immunostained with either rabbit CGRP (1:300; Peninsula Laboratories International Inc, San Carlos, CA) or P2X3 (1:200; Neuromics Inc, Edina, MN) antibody at 4˚C overnight, followed by incubation with the corresponding secondary antibody conjugated with Alexa Fluor 594 (1:300; Life Technologies Inc) for 2 hours. Subsequently, the sections were incubated with 5% goat serum and 0.2% Triton X-100 in PBS for 2 hours, and then incubated with donkey antimouse IgG (1:10; Jackson ImmunoResearch Laboratories Inc, West Grove, PA) in PBS for 1 hour. The sections were immunostained with mouse b-tubulin antibody (1:500; BioLegend Inc, San Diego, CA) at 4˚C overnight, followed by incubation with goat anti-mouse IgG2a, Fcg specific, conjugated with Alexa Fluor 488 (1:300; Jackson ImmunoResearch Laboratories Inc) for 2 hours. For GFRa-1 and GFRa-2 experiments, the sections were incubated with CGRP or P2X3 antibody followed by rabbit secondary antibody conjugated with Alexa Fluor 594 as described above. Then, the sections were immunostained with either goat GFRa-1 (1:1000; R&D Sytems Inc) or GFRa-2 antibody (1:1600; R&D Systems Inc) at 4˚C overnight, followed by incubation with the corresponding secondary antibody conjugated with Alexa Fluor 488 for 2 hours. All sections were counterstained with 49,6-diamino-2-phenylindole in the mounting medium (Vector Laboratories, Burlingame, CA). Images were captured from 10 to 12 skin sections from each animal at 203 magnification (4-6 mice per group) and evaluated by a trained observer blinded to the treatment condition. The number of labeled nerve fibers crossing the dermal-epidermal junction was counted. To accurately count CGRP1 or P2X31 nerve fibers, only those coexpressing b-tubulin were counted. The length of the dermal-epidermal junction (in millimeter) was measured using ImageJ. Epidermal nerve fiber density (ENFD) was calculated as the number of epidermal nerve fibers divided by the length of the dermal-epidermal junction.
Data analysis
Between-group comparisons were made by 1-way analysis of variance (ANOVA) followed by the Bonferroni posttest or by unpaired t test. In all cases P , 0.05 was considered to be significant.
Results
Increase in epidermal nonpeptidergic fiber density in psoriatic skin
To investigate whether total ENFD is altered in imiquimodinduced psoriasis skin, we quantified epidermal nerve fibers on day 0 (naive control), day 2 (early phase of model), and day 7 (late phase of model) of imiquimod treatment. 23 An antibody against b-tubulin was used to visualize all nerve fibers present in the epidermis. Total ENFD was not different among the naive control, early phase, and late phase groups (day 0: 33.9 6 6.4 nerve fiber counts/mm epidermis; day 2: 30.5 6 2.9 counts/mm; day 7: 29.9 6 2.9 counts/mm) (Fig. 1A-C) . Next, ENFD was quantified with a focus on peptidergic and nonpeptidergic fibers. Antibodies against CGRP and P2X3 were used to visualize peptidergic and nonpeptidergic fibers in the epidermis, respectively. The density of CGRP-positive peptidergic fibers was significantly decreased on days 2 and 7 compared with the control group (day 0: 22.5 6 1.4 counts/mm; day 2: 6.7 6 1.0 counts/mm; day 7: 3.3 6 0.3 counts/mm) (Fig. 1D-F) . By contrast, the density of P2X3-positive nonpeptidergic fibers was significantly increased on days 2 and 7 compared with the control group (day 0: 11.6 6 0.4 counts/mm; day 2: 21.5 6 2.7 counts/mm; day 7: 19.4 6 1.9 counts/mm) (Fig. 1G-I ).
GFRa-1 and GFRa-2 expression in epidermal nonpeptidergic fibers
To confirm that most nonpeptidergic epidermal nerve fibers express GFRa-1 and/or GFRa-2 in the imiquimod-treated psoriasis model, as under normal conditions, we doubleimmunostained day 0, day 2, and day 7 skin with antibodies against P2X3 and either GFRa-1 or GFRa-2. Most P2X3-positive epidermal fibers were also either GFRa-1-positive or GFRa-2-positive (GFRa-1: 88.6 6 4.3% on day 0, 78.5 6 2.9% on day 2 and 77.4% 6 2.9% on day 7; GFRa-2: 90.0 6 1.6% on day 0, 79.4 6 1.6% on day 2 and 80.4 6 0.5% on day 7; n 5 4/group) (Fig. 2) . There was a significant decrease in the proportion of GFRa-2-positive P2X3 nerves from day 0 to day 2 (10.6% decrease) and from day 0 to day 7 (9.6% decrease) (P , 0.05, 1-way ANOVA followed by Bonferroni posttest, F (2,9) 5 19.68). By contrast, only about 25% of CGRP-positive epidermal nerves coexpressed either GFRa-1 or GFRa-2, with no change between day 0 and day 2 (GFRa-1: 24.9 6 1.8% on day 0 and 24.6 6 5.3% on day 2; GFRa-2: 21.9 6 1.8% on day 0 and 26.4 6 7.4% on day 2; n 5 4/group).
Increased neurturin expression in psoriatic skin
To investigate the role of growth factors in increased nonpeptidergic ENFD in the psoriatic skin, mRNA expression of GDNF and NRTN was measured on days 0, 1, and 6. These time points were chosen to allow time for translation of mRNA, signaling, and nerve growth before the observed changes in ENFD on days 2 and 7. Glial cell line-derived neurotrophic factor mRNA decreased gradually over time and showed a significant reduction on day 6 (P , 0.05, F (2,15) 5 7.726, Fig. 3A ). Neurturin mRNA increased gradually over time and showed a significant increase on day 6 (P , 0.05, F (2,11) 5 6.52, Fig. 3B ). These results imply that NRTN, and not GDNF, is responsible for the increase in epidermal nonpeptidergic fiber density. In addition, NRTN immunoreactivity was strongly detectable in keratinocytes on day 2 ( Fig. 3D) and moderately detectable on day 7 (Fig. 3E ) compared with day 0 (Fig. 3C) . Neurturin immunoreactivity was completely abolished by preabsorption of antibodies with NRTN (Fig. 3F) .
Reduction in epidermal nonpeptidergic fiber density and spontaneous scratching by blockage of neurturin/ GFRa-2 signaling
Finally, we investigated whether blocking NRTN/GFRa-2 signaling with an NRTN-neutralizing antibody could reduce spontaneous scratching in the imiquimod-induced psoriasis model by inhibiting the increase of nonpeptidergic ENFD. Either a low dose or high dose of the neutralizing antibody was injected intradermally into the imiquimod treatment area once daily for days 1 to 7 of the model. These mice were compared with those injected with a goat IgG control antibody. (Fig. 4A) . By contrast, NRTN-neutralizing antibody treatment did not affect the CGRP-positive ENFD on either day 2 or 7 (day 2 control: 7.4 6 0.9 counts/mm; day 2 NRTN [low dose]: 6.0 6 0.2 counts/mm; day 7 control: 7.5 6 0.5 counts/mm; day 7 NRTN [low dose]: 7.0 6 0.9 counts/mm; day 7 NRTN [high dose]: 7.8 6 0.5 counts/mm; P , 0.05 unpaired t test or 1-way ANOVA followed by Bonferroni test, 4 to 6 mice/group) (Fig. 4B) . Intriguingly, the neutralizing antibody for NRTN dose-dependently reduced spontaneous scratching behavior in the imiquimod-induced psoriasis model on day 7, but not on day 2 (Fig. 4C) . Of note, we did not observe a recovery in external skin appearance, such as scaliness and erythema, after treatment with the neutralizing antibody (data not shown).
Discussion
Psoriatic itch is often intractable, and its mechanisms are still unknown. Here we show the following: (1) the density of nonpeptidergic epidermal nerve fibers was significantly increased in the imiquimod-induced psoriasis model, while the density of peptidergic fibers significantly decreased. (2) Neurturin expression increased in the skin of imiquimod-treated mice, whereas GDNF expression decreased. (3) Injection of an NRTNneutralizing antibody into the imiquimod treatment area significantly inhibited the increase in nonpeptidergic nerve density as well as spontaneous scratching, a behavior associated with chronic itch. These findings indicate that NRTN, by promoting an increase in nonpeptidergic epidermal nerve fibers, contributes to chronic itch in imiquimod-treated mice. Therefore, inhibition of NRTN could be a potential treatment for chronic itch in psoriasis. In this study, NRTN expression was increased in the epidermis of imiquimod-treated mice. Previous studies have shown that NRTN KO mice exhibited a reduction in GFRa-2-positive neurons, 9 and GFRa-2 KO mice showed a reduced density of nonpeptidergic nerve innervation. 13, 15 Conversely, genetically induced NRTN overexpression in keratinocytes increased the total epidermal nerve density without affecting epidermal peptidergic fiber density. 35 These findings support the idea that NRTN is a crucial mediator of nonpeptidergic ENFD. In this study, upregulation of NRTN in psoriatic skin plausibly contributes to the increase in epidermal nonpeptidergic fiber density through GFRa-2. The percent of GFRa-2-positive P2X3 fibers significantly decreased from day 0 to day 2, perhaps because of overexpression of NRTN leading to downregulation of GFRa-2. 20 In addition, although NRTN preferentially binds to GFRa-2, it can also act through GFRa-1. 1, 6, 27 Thus, NRTN may increase nonpeptidergic ENFD partially through GFRa-1. By blocking these pathways, the NRTN-neutralizing antibody treatments prevented the increase in epidermal nonpeptidergic fiber density in the psoriatic skin.
Most epidermal P2X3-immunoreactive fibers expressed GFRa-2. Recent studies using single-cell RNA-sequencing analyses of dorsal root ganglia neurons revealed that the cluster containing P2X3-and GFRa-2-positive neurons had high expression of Mas-related G-coupled protein receptor (Mrgpr) D, MrgprB5, transient receptor potential ankyrin 1, transient receptor potential canonical 3, voltage-gated sodium channel 1.8/9, lysophosphatidic acid receptors 3 and 5, and serotonin 2A receptors. 14, 33 These receptors have established roles in itch transmission. 10, 16, 37, 39 This suggests that nonpeptidergic nerve fiber density may be an important factor in many different itch conditions. Further studies are needed to determine which endogenous mediators are most important for psoriatic itch.
We previously reported that the imiquimod-induced psoriasis model exhibited histamine-dependent itch in the early phase (day 2) and histamine-independent itch in the late phase (day 7). 23 In this study, although the NRTN-neutralizing antibody inhibited the increase in nonpeptidergic ENFD in both early and late phases of the psoriasis model, it only inhibited spontaneous itch in the late phase. Thus, it is plausible that nonpeptidergic fibers are not involved in spontaneous itch in the early phase, even though their epidermal density increased. We speculate that the increase in nonpetidergic nerve density may precede the availability of ligands that activate these fibers to evoke itch. A previous study found an increase in ENFD in mice after only 1 acetone treatment, although 3 daily acetone/ether applications are typically necessary to evoke scratching behavior in the dry skin itch mouse model. 31, 34 We also report a decrease in peptidergic ENFD in this model. There is conflicting evidence as to whether peptidergic epidermal nerve fibers are increased or decreased in psoriasis patients. 12, 21, 22, 29 These differences could be due to duration of the lesions and/or variations in the progression of the disease. 17, 19 Recently, Wong et al. 38 reported that total ENFD was increased in imiquimod-treated psoriasis mice through the action of vascular endothelial growth factor-A. However, they measured ENFD by total area of PGP9.5-positive nerve staining in the epidermis, which may indirectly reflect factors such as branching or fiber thickness. In our study, we counted the number of epidermal nerve fibers crossing epidermal-dermal junction and did not find an increase in total ENFD in imiquimod-induced psoriasis mice, which is consistent with another study using a similar counting method. 28 Vascular endothelial growth factor-A receptors are expressed by a majority of sensory nerves, including both peptidergic and nonpeptidergic nerves, 26 leaving open the possibility that vascular endothelial growth factor-A may also be involved in psoriatic itch mediated by nonpeptidergic nerve fibers.
In summary, this is the first study to examine the role of nonpeptidergic nerve fibers in a model of psoriasis. We demonstrate that NRTN is involved in enhanced nonpeptidergic ENFD in the imiquimod-induced mouse model of psoriasis, and these nonpeptidergic fibers may be linked to late-phase, histamine-independent itch. Further studies are necessary to fully explore the factors that drive increased NRTN expression and the endogenous pruritogens that act on these epidermal nonpeptidergic fibers. Finally, it will be of significant importance to clarify the role of NRTN in pruritic dermatological diseases in humans.
